halofuginone

Also Known As:

(+)-halofuginone; (+-)-trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3H)-quinazolinone; (+-)-trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3H)-quinazolinone monohydrobromide; (-)-halofuginone; (-)-halofuginone hydrobromide; 4(3H)-quinazolinone, 7-bromo-6-chloro-3-(3-((2R,3S)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-, hydrochloride (1:1), rel-; 4(3H)-quinazolinone, 7-bromo-6-chloro-3-(3-((2S,3R)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-, hydrobromide (1:1); 4(3H)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, hydrobromide, trans-(+-)-; 4(3H)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, trans-, mono(2-hydroxypropanoate)(salt); 6-chloro-7-bromo-(+)-febrifugine; 6-chloro-7-bromofebrifugine; 7-bromo-6-chloro-3,3-(3-hydroxy-2-piperidyl)acetonyl-4(3H)-quinazolinone-hydrolactate; 7-bromo-6-chloro-3-(3-((2R,3S)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3H)-quinazolinone; 7-bromo-6-chloro-3-(3-((2S,3R)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3H)-quinazolinone; 7-bromo-6-chloro-3-(3-((2S,3R)-3-hydroxy-2-piperidyl)-2-oxo-propyl)quinazolin-4-one hydrobromide; 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3H)-quinazolinone; 7-bromo-6-chlorofebrifugine; Cebegine; Halagon; Halocur; RU 19110; RU-19110; RU19110; Stenorol; chloro-bromofebrifugine; chlorobromofebrifugine; halofuginon; halofuginone HBr; halofuginone HCl; halofuginone hydrobromide; halofuginone hydrobromide, (-)-; halofuginone hydrochloride; halofuginone lactate; halofuginone monohydrobromide; halofuginone monohydrochloride; halofuginone, (+)-; halofuginone, (-)-; halofunginone; trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3H)-quinazolinone

Networked: 264 relevant articles (58 outcomes, 52 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - halofuginone: 264
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - Quinazolinones: 124
        halofuginone: 264

Experts

1.	Pines, Mark: 39 articles (06/2021 - 05/2002)
2.	Nagler, Arnon: 19 articles (06/2015 - 05/2002)
3.	Halevy, Orna: 17 articles (06/2021 - 06/2006)
4.	Genin, Olga: 14 articles (06/2021 - 02/2007)
5.	Nagler, A: 7 articles (04/2007 - 11/2000)
6.	Barzilai-Tutsch, Hila: 6 articles (01/2020 - 01/2013)
7.	Pines, M: 6 articles (04/2007 - 11/2000)
8.	Genina, Olga: 5 articles (06/2006 - 09/2002)
9.	Bian, Zhao-Xiang: 4 articles (01/2022 - 09/2015)
10.	Mazitschek, Ralph: 4 articles (03/2021 - 06/2009)

Related Diseases

1.	Infections 09/01/1986 - "Halofuginone was also highly effective in preventing buildup of infection in pens contaminated by indirect means (movement by caretakers through the pens, etc.). " 08/01/2012 - "The histological slide examination noted that halofuginone was effective when provided 0-2 days post inoculation but only partially effective when applied 3-7 days post infection. " 02/01/1991 - "The efficacy of halofuginone lactate against natural Cryptosporidium parvum infection in 150 neonatal market calves of a mixed Belgian breed was tested. " 05/01/2019 - "The objective of this study was to compare the effect of non-GMO Saccharomyces cerevisiae fermentation products (SCFP) with that of a halofuginone treatment against Cryptosporidium parvum infection in pre-weaned calves on a commercial dairy farm. " 10/01/2009 - "For prophylactic treatment, halofuginone had an effect on infection and diarrhoeal prevalence on study days 4 and 7, but the control group had significantly lower infection prevalence than the halofuginone treated group on study day 21. "
2.	Fibrosis (Cirrhosis) 04/01/2016 - "Compared with control mice, on Day 28 post-transplant, lung grafts of mice treated with halofuginone showed a significant reduction in the percentage of obliterated airways (6.8 ± 4.7% vs 52.5 ± 13.8%, p < 0.01), as well as significantly reduced parenchymal fibrosis (5.5 ± 2.3% vs 35.9 ± 10.9%, p < 0.05). " 08/01/2010 - "We evaluated the efficacy of halofuginone in reducing fibrosis in the dy(2J)/dy(2J) mouse model of congenital MD. " 11/01/2008 - "Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone." 01/01/2017 - "Halofuginone (HF) is a well-known anti-fibrosis agent in preclinical and clinical studies which exerts its effect via inhibition of TGF-β/Smad3 signaling pathway. " 04/01/2014 - "More recently studies have also shown that halofuginone acts as an agent capable of reducing fibrosis, an indication with clinical relevance for several disease states. "
3.	Cryptosporidiosis 09/01/2010 - "Halofuginone lactate was shown to be effective in reducing clinical signs of cryptosporidiosis and environmental contamination. " 12/01/2007 - "Halofuginone treatment was effective in preventing and in reducing the death rate of cryptosporidiosis in these flocks." 12/01/2007 - "Halofuginone was effective in the treatment of diarrhoea caused by cryptosporidiosis (P < 0.01). " 12/01/2007 - "The first trial was designed to assess the efficacy of halofuginone in treating lamb diarrhoea caused by cryptosporidiosis, and in preventing the disease, using two schemes; halofuginone given for seven and for three consecutive days respectively. " 01/01/2021 - "A prior systematic review on the efficacy of halofuginone (HFG) treatment to prevent or treat cryptosporidiosis in bovine calves was inconclusive. "
4.	Neoplasms (Cancer) 09/01/2003 - "In vivo magnetic resonance imaging analysis of tumors in halofuginone-treated animals showed a significant reduction of vascular functionality. " 11/01/2022 - "Additionally, halofuginone reduced ELT3 tumor growth in xenograft tumor animal model. " 10/01/2021 - "We found that halofuginone administration decreased the number of pancreatic intraepithelial neoplasias in pancreas-specific Kras and p53 mutant (KPC) mice. " 10/17/2017 - "Furthermore, halofuginone decreased tumor-take and growth of orthotopic-tumors. " 10/17/2017 - "Halofuginone decreased immunostaining of phospho-Smad2/3 and phospho-Smad1/5/8 in cancer cells in vivo. "
5.	Neoplasm Metastasis (Metastasis) 01/01/2015 - "In animal xenograft model, the addition of halofuginone to irradiation inhibited the growth of subcutaneously implanted xenografts, reduced hepatic and pulmonary metastases, and improved survival of the mice. " 06/10/2015 - "Moreover, halofuginone inhibits the TGF-β/Smad3 cascade and the response of TGF-β key targets involved in the metastases dissemination process such as MMP-2. " 01/01/2015 - "The changes associated with antitumor effect of halofuginone, including hepatic and pulmonary metastases and survival, were observed. " 10/17/2017 - "Here we demonstrate that halofuginone is an effective therapy for the treatment of bone metastases, through multiple actions that include inhibition of TGFβ and BMP-signaling. " 10/17/2017 - "Thus, halofuginone reduces breast and prostate cancer bone metastases in mice and combined with treatment currently approved by the FDA is an effective treatment for this devastating complication of breast and prostate-cancer."

Related Drugs and Biologics

1.	halofuginone
2.	Collagen
3.	Monensin (Coban)
4.	Nicarbazin
5.	Micelles
6.	tocophersolan
7.	Collagen Type I (Type I Collagen)
8.	Transforming Growth Factor beta (TGF-beta)
9.	Matrix Metalloproteinases (MMPs)
10.	Decoquinate

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Radiotherapy
4.	Ligation
5.	Oral Administration